Mark Posner, MD
Allergy & Immunology · Blue Bell, PANPI 1508869637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 515 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,471 and has fallen 71.4% since, to $706 in 2025.
Across 515 payments — averaging $21.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Sanofi$1K
- GSK$1K
- Regeneron Healthcare Solutions, Inc.$865
- CSL Behring$769
- Pfizer$658
- plus $4K from 26 others
What the payments were for
- Food & beverage$10,69498%
- Education$2262%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 111 | $2,264 |
| Sanofi | 57 | $1,247 |
| GSK | 53 | $1,098 |
| Regeneron Healthcare Solutions, Inc. | 27 | $865 |
| CSL Behring | 37 | $769 |
| Pfizer | 45 | $658 |
| Kaleo, Inc. | 33 | $625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $595 |
| Genentech USA, Inc. | 20 | $456 |
| Alk-abello, Inc | 9 | $283 |
| Amgen(2 entities) | 7 | $241 |
| Biocryst US Sales Co., LLC | 10 | $226 |
| Blueprint Medicines Corporation | 6 | $218 |
| Grifols USA, LLC | 9 | $172 |
| Covis Pharma GmbH | 9 | $135 |
| Bio Products Laboratory USA, Inc. | 9 | $132 |
| Octapharma USA, Inc. | 6 | $122 |
| Boehringer Ingelheim | 6 | $121 |
| Optinose US, Inc. | 7 | $115 |
| Sanofi-aventis U.S. LLC | 2 | $115 |
| Shire North American Group Inc | 4 | $92 |
| Teva Pharmaceuticals USA, Inc. | 4 | $65 |
| Novartis | 3 | $50 |
| AbbVie | 3 | $49 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
| Organon | 3 | $41 |
| Merck | 2 | $28 |
| Verona Pharma, Inc. | 1 | $26 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| LEO Pharma Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,920 in reported general payments places this provider in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 18 | $49,096 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $26,684 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $17,277 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $16,153 |
| Cromolyn Sodium | 25 | $14,655 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $11,292 |
| DuleraMometasone/Formoterol | 13 | $9,812 |
| Arnuity ElliptaFluticasone Furoate | 34 | $9,240 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 23 | $7,826 |
| Qvar RedihalerBeclomethasone Dipropionate | 15 | $7,144 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $7,037 |
| Epinephrine | 31 | $5,025 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 32 | $3,834 |
| Azelastine Hcl | 131 | $3,495 |
| Montelukast Sodium | 211 | $2,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $1,098 | $52,07788 claims |
| AstraZenecaSymbicort | $2,264 | $11,29230 claims |
| MerckDulera | $28 | $9,81213 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $65 | $7,14415 claims |
| Hikma Pharmaceuticals USAEpinephrine | $20 | $5,02531 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 175 allergy & immunology providers in Pennsylvania.
Other allergy & immunology in Blue Bell
- Robert AnolikBlue Bell$60K
- David KrauseBlue Bell$14K
- Patrick VannelliBlue Bell$7K
- Matthew FoggBlue Bell$7K
- Christine MalloyBlue Bell$7K
- Drew WeissmanPhiladelphia$12.8M
- Eric SchenkelBethlehem$845K
- Sergei BelenkyPittsburgh$775K
- Timothy CraigHershey$564K
- Sandra GawchikUpland$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.